{"filings":[{"id":564078,"accession_number":"0001193125-26-233429","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2026-05-21T12:00:44+00:00","items":["7.01"],"status":"ready","headline":"Orthofix cuts FY2026 guidance as CMS cuts bone stimulator reimbursement ~10%","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS reduced Medicare reimbursement for HCPCS codes E0747, E0748, E0760 by ~10% effective May 18, 2026.","FY2026 net sales guidance lowered to $838M-$848M; non-GAAP adjusted EBITDA to $90M-$93M.","Company no longer expects positive free cash flow in FY2026; three-year financial targets abandoned.","Further CMS changes could require additional outlook revisions; long-term impact still being evaluated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99434,"accession_number":"0001193125-26-204999","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix Q1 pro forma revenue $196.4M +2.7% constant currency; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $(20.9)M vs $(53.1)M prior year; adjusted EBITDA $9.7M (4.9% of pro forma sales) vs $11.4M (6.0%) prior year.","Global Spine Fixation +6%, Therapeutic Solutions +5%, Limb Reconstruction +10% reported (+3% constant currency).","Reaffirms FY2026 net sales $850M-$860M, adjusted EBITDA $95M-$98M, positive free cash flow.","Cash $120.9M at March 31, 2026; plans to repay $424M 0.875% exchangeable notes due June 2026.","Distributor transitions largely behind; expects improved commercial execution and product launches later in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":196708000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99433,"accession_number":"0001193125-26-148853","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Orthofix reports prelim Q1 net sales $196.7M, realigns spine leadership, Reinhardt to depart","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q1 net sales $196.7M; reported constant currency +0.4%, pro forma constant currency +2.7% YoY.","FY 2026 guidance reaffirmed: net sales $850M-$860M, adj. EBITDA $95M-$98M, positive FCF ex-legal settlements.","President, Global Spine Max Reinhardt to depart on/about June 12, 2026; role eliminated in realignment.","Key spine leaders (Bannigan, Sienkiewicz, Winge) now report directly to CEO; Fisher expands to Biologics.","M6 disc discontinuation impact fell to $0.3M in Q1 from $4.4M in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":196708000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115419,"accession_number":"0001193125-26-065184","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix Q4 net sales $219.9M, net loss narrows; FY26 guidance $850-860M sales, $95-98M adj. EBITDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $(2.2)M vs $(29.1)M YoY; adjusted EBITDA $29.2M (13.4% margin), up 230 bps.","Full-year 2025 net sales $822.3M (+2.9% reported); pro forma $811.9M (+4.1% constant currency).","FY25 net loss $(92.2)M, improved from $(126.0)M; free cash flow $3.1M (ex-M6 restructuring).","2026 guidance: net sales $850-860M (~5.5% pro forma CC growth); adj. EBITDA $95-98M.","Three-year targets (2026-28): 6.5-7.5% sales CAGR, mid-teens EBITDA margin by 2028, positive FCF."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":822312000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131835,"accession_number":"0001193125-25-263529","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix Q3 pro forma net sales up 5.7%; adj EBITDA margin expands to 12.1%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Pro forma net sales $203.4M, +5.7% constant currency vs Q3 2024; reported net sales $205.6M.","Non-GAAP adj EBITDA $24.6M (12.1% margin) vs $19.2M (9.8%) prior year; seven consecutive quarters of expansion.","U.S. Spine Fixation sales +8%, Bone Growth Therapies +6%, Global Orthopedics constant currency +6%.","FY2025 pro forma net sales guidance narrowed to $810-814M; adj EBITDA guidance raised low end to $84-86M.","Free cash flow positive $2.5M in Q3; positive FCF expected for full year 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":602401000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148428,"accession_number":"0000950170-25-102383","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix Q2 net sales $203.1M (+2.3%); adj. EBITDA $20.6M; positive FCF; reaffirms FY25 guide","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Pro forma net sales (ex-M6) $200.7M, +3.5% constant currency; net loss $(14.1)M vs $(33.4)M prior year.","Non-GAAP pro forma adjusted EBITDA $20.6M (10.3% margin), up 24% YoY; six straight quarters of margin expansion.","Free cash flow positive $4.5M in Q2; cash, equivalents and restricted cash $68.7M.","U.S. Spine Fixation sales +5% (volume +7%); BGT Fracture +7%; U.S. Orthopedics +28%.","FY2025 guidance reaffirmed: pro forma net sales $808-816M, adj. EBITDA $82-86M, positive FCF."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":396767000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167226,"accession_number":"0000950170-25-088194","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Orthofix holds 2025 annual meeting; all director nominees elected, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 10 board nominees elected; Vickie Capps received 29.66M votes for, 0.91M against.","Say-on-pay advisory resolution approved with 30.00M votes for (97.9% of votes cast).","Ratification of Ernst & Young as auditor passed with 35.02M votes for (99.0% of votes cast).","Board appointed Vickie L. Capps to both Audit & Finance and Compensation & Talent Development committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167225,"accession_number":"0000950170-25-063953","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix Q1 net loss $53.1M; lowers FY2025 net sales guidance to $808-816M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 pro forma net sales $189.2M, up 4.3% constant currency YoY; GAAP net loss $53.1M ($1.35/share) vs $36.0M loss year ago.","Non-GAAP pro forma adjusted EBITDA $11.4M (6.0% margin), up 49% vs $7.7M in Q1 2024; adjusted gross margin 70.3%.","Lowered FY2025 net sales guidance to $808-816M (pro forma) from $818-826M; reaffirms adjusted EBITDA $82-86M and positive free cash flow.","U.S. Spine Fixation +4%, BGT +5%, Global Orthopedics constant currency +11% YoY; TrueLok Elevate TBT System received FDA clearance.","Management cites commercial channel optimization causing temporary softness; expects growth to normalize after distributor transitions."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":193646000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167224,"accession_number":"0000950170-25-051645","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"Orthofix enters new 12.5-year Carlsbad lease with total cost $34.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New lease effective April 1, 2025 for Carlsbad office (5770 Armada Drive); term through Oct 31, 2037.","Monthly rent includes 3.5% annual increases; total pre-tax occupancy cost estimated $34.6M.","Company also responsible for real estate taxes, insurance, utilities, and other expenses.","Prior sublease terminated as of April 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184577,"accession_number":"0000950170-25-037630","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Orthofix appoints Vickie Capps to board of directors, effective March 11, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Capps is a CPA and former CFO of DJO Global; brings expertise in global ops, business development, and corporate finance.","Board size increased from 9 to 10 directors; Capps will serve as an independent director.","Capps currently serves on boards of Amedisys, Janux Therapeutics, Enable Injections, and Breg.","No transactions requiring Item 404(a) disclosure; standard director indemnification agreement to be entered.","Capps to participate in non-employee director compensation program; committee assignments to be determined later."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184576,"accession_number":"0000950170-25-026062","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix reports record Q4 net sales of $215.7M (+8% YoY); guides FY25 sales $818-826M, adj. EBITDA $82-86M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $215.7M (+8% YoY); record BGT $63.9M (+9%) and Global Orthopedics $35.8M (+18% cc).","Q4 net loss $(29.1)M ($(0.75)/share); adjusted EBITDA $23.9M (11.1% margin) vs $19.6M (9.8%) in Q4 2023.","FY24 net sales $799.5M (+7%); net loss $(126.0)M vs $(151.4)M; adjusted EBITDA $67.4M (8.4% margin) vs $46.3M.","Discontinuing M6 artificial disc lines ($23.4M 2024 sales); guides FY25 sales $818-826M (ex-M6, +6.5% cc) and adj. EBITDA $82-86M.","Long-term CAGR target raised to 6.5-7.5%; Q4 free cash flow $15.2M; cash $85.7M at year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":799491000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201149,"accession_number":"0000950170-24-124165","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Orthofix enters $275M secured credit facility with Oxford Finance; repays Blue Torch loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New credit agreement provides $160M term loan, $65M delayed draw, and up to $50M discretionary facility, maturing Nov 2029.","Interest rate: greater of 8.75% or 5.75% plus 1-month SOFR; facility fee 1.5% of each funded tranche.","Company terminated prior $275M credit agreement with Blue Torch Finance dated Nov 2023.","Covenants require min $45M unrestricted cash at closing, $15M ongoing, and max 4.0x total debt-to-EBITDA leverage.","Delayed draw Term B available from Jan 2025 to Jun 2026 subject to leverage compliance; Term C at Oxford's discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201148,"accession_number":"0000950170-24-122777","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix Q3 net sales $196.6M (+7%), adjusted EBITDA $19.2M, introduces 2027 targets","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $196.6M, +7% YoY; U.S. Spine Fixation +18%, U.S. Orthopedics record quarter +15%.","Net loss $(27.4)M vs $(28.9)M prior year; adjusted EBITDA $19.2M, margin 9.8% vs 7.3%.","Free cash flow positive $5.9M in Q3; new $275M credit facility announced.","Reiterates FY2024 guidance: net sales $795-800M, adjusted EBITDA $64-69M.","Introduces 2027 targets: 6-7% revenue CAGR, mid-teens adjusted EBITDA margin, positive FCF."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":583834000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217172,"accession_number":"0000950170-24-091199","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix Q2 net sales $198.6M (+6% YoY); raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $198.6M, +6% YoY; net loss $(33.4M) vs $(39.4M) prior year; EPS $(0.88).","Non-GAAP adjusted EBITDA $16.6M (8.4% margin), +310 bps YoY from $9.9M.","Bone Growth Therapies +12% YoY; U.S. Spine Fixation +12% YoY; Global Orthopedics +5%.","FY2024 net sales guidance raised to $795-800M; adjusted EBITDA to $64-69M.","Expects positive free cash flow in H2 2024; appointed four new executive team members."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":387228000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236954,"accession_number":"0000950170-24-075288","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Orthofix President of Global Orthopedics departing; shareholders approve 5M share LTIP increase","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kimberley A. Elting, President Global Orthopedics, departing on or about July 5, 2024; will receive severance and accelerated vesting.","Shareholders approved Amendment No. 5 to LTIP, increasing shares reserved by 5,000,000 to 16,275,000 total.","Shareholders approved Amendment No. 4 to Stock Purchase Plan, increasing shares by 1,250,000 to 4,850,000 total.","Michael M. Finegan appointed Chair of the Board; remaining committee chairs also appointed effective June 18, 2024.","All eight director nominees elected; advisory vote on executive compensation passed with 96.8% support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236953,"accession_number":"0000950170-24-053961","cik":884624,"company_name":"Orthofix Medical Inc.","ticker":"OFIX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Orthofix Q1: net sales $188.6M (+7.7%), net loss narrows to $36M; raises FY sales outlook to $790-795M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $188.6M, +7.7% YoY; Bone Growth Therapies +10%, U.S. Spine Fixation +16%, U.S. Orthopedics +23%.","GAAP net loss $(36.0)M ($0.95 loss per share) vs $(60.9)M ($1.71) prior year; adjusted EBITDA $7.7M (4.1% of sales).","FY2024 net sales guidance raised to $790-795M (from $785-795M); adjusted EBITDA guidance reaffirmed at $62-67M.","Cash and cash equivalents $29.5M; $125M drawn on $150M credit facility."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":188608000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":376729830.94370526,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}